Anne Portwich - Profile and Investment Details

Investor Profile

Anne Portwich is a Venture Capital, Private Equity Firm, Investor based in Amsterdam, North Holland, The Netherlands with a diverse investment portfolio that includes companies such as FoRx Therapeutics, Cybin, Cardiac Dimensions, AM Pharma, Sapiens Steering Brain Stimulation, Syntaxin, ActoGeniX N.V., MedEye, Asoyia, eTheRNA immunotherapies, Vico Therapeutics, DNA Script, Hyperion Therapeutics, VarmX, Hybrigenics, Perfuze, Atlantic Therapeutics, Sequana Medical, Xeltis, Pronota, ImCheck Therapeutics, Prosensa, Orphazyme, Heart Metabolics, ViCentra, Nexstim, XyloCor Therapeutics, Mendor, INNOVO by Atlantic Therapeutics, BMEYE, OneProjects, Cardior Pharmaceuticals, Seahorse Bioscience, Nkarta TherapeuticsSimplify Medical, Luxendo, Binx Health, Affimed, Pasteuria Bioscience, Artios Pharma, Cellerix, GTX medical, IlluminOss Medical, Endotronix, Kreatech Diagnostics, Nouscom, Celladon, Mint Solutions, Neuravi, Rainier Therapeutics, Rotation Medical, Alizé Pharma, Vivasure Medical, Immunic, Kuros Biosciences, Merus, Promethera Biosciences, Neurent Medical, Kiadis Pharma, NUA SURGICAL, SNIPR Biome, Harvest Automation, arGEN-X, Curetis, Vivoryon Therapeutics, ActoGeniX, iSTAR Medical, Pharvaris, Cobalt Technologies, Trinity Biosystems, OxThera, Arvelle Therapeutics, Vivendy Therapeutics, . Over time, Anne Portwich has demonstrated experience in supporting a range of businesses across various sectors.

While it is not publicly confirmed whether Anne Portwich is currently seeking new investment opportunities, their past investments provide valuable insight into the types of projects and industries that have attracted their attention.

Startups and entrepreneurs operating in sectors related to Health Care, DeepTech, Wellness, Investment Management, Energy, Life Science, Mobile, Manufacturing, Biotechnology, Productivity Software, UK Startups, Utilities, Health Diagnostics, Social Impact, Renewable Energy, Medical, B2B, Therapeutics, Health Tech, Media and Entertainment, Pharmaceuticals may find it worthwhile to explore potential connections with Anne Portwich, as their portfolio suggests a familiarity and interest in this area.

Understanding Anne Portwich’s investment history can offer useful context for founders considering outreach and help identify whether there is a potential fit based on strategic alignment and market focus.